EU Approves Pfizer’s HYMPAVZI for Hemophilia Patients With Inhibitors
Pfizer Inc. announced that the European Commission has approved an expanded indication for HYMPAVZI, allowing its use in patients aged 12 years and older with hemophilia A or hemophilia…
Read More...
Read More...
